CEO Letter To Shareholders January 6, 2015: Dear Shareholders, 2014 was a year of transition for Immune Pharmaceuticals. We obtained a NASDAQ listing, raised
over $20 million in equity, reduced past liabilities and strengthened our cash position.
BIO CEO & Investor Conference
Waldorf Astoria Hotel, New York
Presentation Date: February 10, 2015
Presentation Time: 2:00: PM
Presentation Room: Duke of Windsor.
IMMUNE is focused on developing the next generation of monoclonal antibodies to
address significant unmet medical needs in
the treatment of cancer and inflammatory diseases. Our goal is to improve patients’ lives through targeted medicine.